2025-04-09T11:00:10+00:00 2024-06-30 350921680 CROWE LLP 4801 Olympia Park Plaza Suite 4000 Louisville KY 402412098 990 2023-07-01 260303542 Hoosier Cancer Research Network Inc HOOS 3179212050 7676 Interactive Way 120 Indianapolis IN 462782736 Brian Stemme CEO 3179212050 2025-04-09 true Kim Scifres P01316095 5023263996 2025-04-09 2023 2025-03-06 01:10:19Z Brian Stemme 7676 Interactive Way 120 Indianapolis IN 462782736 14469158 false X www.hoosiercancer.org X 2007 IN To reduce the burden of cancer by advancing cancer research, education, and patient advocacy. 10 10 64 10 0 0 695094 7792 13210958 13602952 195606 286702 0 0 14101658 13897446 0 0 0 0 5050230 5252112 0 0 0 6980422 8959647 12030652 14211759 2071006 -314313 13703057 14561673 3864540 4796232 9838517 9765441 To form unparalleled relationships between academic, community, pharmaceutical, and biotech collaborators with the goal of advancing cancer research, education, and patient advocacy. false false 11526600 0 12681936 INVESTIGATOR-INITIATED STUDIES - THESE ARE STUDIES CREATED BY NON-INDUSTRY PHYSICIANS, MOST COMMONLY FOR US FROM ACADEMIC INSTITUTIONS BUT POSSIBLY ALSO FROM COMMUNITY SITES, AND THOSE PHYSICIANS SERVE AS SPONSOR-INVESTIGATORS. WHEN WE CONDUCT/MANAGE THESE STUDIES, WE PRESERVE RIGHTS FOR US AND OUR MEMBER INSTITUTIONS TO PUBLISH AND ACCESS DATA FOR THE PUBLIC BENEFIT CONSISTENT WITH OUR TAX EXEMPT PURPOSE. THESE STUDIES MAY BE FUNDED BY INDUSTRY, BUT INDUSTRY IS NOT THE SPONSOR. THESE STUDIES MAY ALSO BE FUNDED BY PHILANTHROPIC ORGANIZATIONS, AND IN SOME CASES PUBLIC AND PRIVATE UNIVERSITIES. THE SPONSOR INVESTIGATOR OWNS THE PROTOCOL AND DATA IN AN IIT AND INDUSTRY GETS TO USE THE DATA. 548916 0 546016 INDUSTRY-SPONSORED STUDIES - ON RARE OCCASIONS, WE GET INVOLVED IN INDUSTRY-SPONSORED STUDIES, MEANING A STUDY INITIATED AND CONDUCTED BY A PHARMACEUTICAL COMPANY. WHEN WE WORK ON THOSE STUDIES, WE PRESERVE RIGHTS FOR US AND OUR SITES TO PUBLISH AND ACCESS DATA FOR THE PUBLIC BENEFIT CONSISTENT WITH OUR TAX-EXEMPT PURPOSE. PHARMA FUNDS THESE STUDIES AND ALSO ACTS AS THE SPONSOR. PHARMA OWNS THE PROTOCOL AND DATA IN THESE STUDIES, AND SITES (AND WE) GET TO USE THE DATA FOR PUBLICATION PURPOSES. 383488 0 375000 BTCRC ADMINISTRATION - HCRN IS THE ADMINISTRATIVE HEADQUARTERS OF THE BIG TEN CANCER REASEARCH CONSORTIUM (BTCRC). EACH MEMBER INSTITUTION PAYS IN DUES WHICH SUPPORT CONSORTIUM OPERATIONS INCLUDING THE BTCRC CHIEF SCIENTIFIC OFFICER, WORKING GROUP COORDINATION, LOI DEVELOPMENT, EVENT MANAGEMENT, AND OVERHEAD. THE BTCRC IS LED BY A STEERING COMMITTEE COMPOSED OF ONE RESEARCHER FROM EACH MEMBER INSTITUTION. 12459004 true false false false false false false false false true false false true true true true false false false false false false false false false false false false true false false false false false false false false false false false false false true false false false true 23 0 true 64 true false false false false false false false false false false false false X 10 10 false false false false false true false true true false false true true true true true true true false false IN X Mark Ingold 3179212050 7676 Interactive Way Ste 120 Indianapolis IN 462782736 Annette Moore MD Secretary 0.5 X X 0 0 0 Chris Fausel Chair 1.0 X X 0 0 0 Chris Wayne Treasurer 0.5 40.0 X X 0 95874 0 Andrew Mesecar PhD Board Member 0.5 X 0 0 0 Brooke Patz Board Member 0.5 40.0 X 0 109558 0 Chris LeMasters Board Member 0.5 X 0 0 0 Jennifer King MD Board Member 0.5 40.0 X 0 52500 0 Patrick Loehrer MD Board Member 0.5 40.0 X 0 294382 0 Rita Assi MD Board Member 0.5 40.0 X 0 41847 0 Tim Lautenschlaeger MD Board Member 0.5 40.0 X 0 40385 0 Tim Ratliff PhD Board Member (until 8/28/23) 0.5 X 0 0 0 Brian Stemme CEO 40.0 X 298940 0 39399 Jeff Smith COO 40.0 X 136449 0 13051 JoLynn Bahr CFO (until Dec 2023) 20.0 X 70308 0 9285 Mark Ingold CFO (Hired Aug 23) 40.0 X 54348 0 6602 Anita Camic Contracts and Quality Assurance Officer 40.0 X 109320 0 11887 Christy Yoder Safety and Regulatory Officer 40.0 X 114623 0 28180 Karen Dutcher General Counsel 40.0 X 153282 0 23590 LeaEtta Hyer Research Development Officer 40.0 X 130676 0 29880 Lisa Wood Research Development Director 40.0 X 108199 0 13233 1176145 634546 175107 7 false true false 0 3282 4510 7792 External Support-Research 541715 13227952 13227952 Other Contract Support 541715 375000 375000 0 0 0 0 13602952 305216 305216 0 0 553198 571712 -18514 0 -18514 -18514 0 0 0 0 0 13897446 13602952 0 286702 628366 518313 110053 3688596 2951321 737275 619168 507718 111450 315982 126156 189826 130 130 37969 37969 11442 11442 1166382 1092536 73846 0 119953 30830 89123 516544 265118 251426 415024 324261 90763 10779 2795 7984 88140 88140 66020 51581 14439 31813 24856 6957 Institutional Research 3782986 3782986 Research Site Support 1369868 1369868 Other Research Services 1261501 1261501 Bad Debt Expense 60971 60971 20125 53 20072 0 14211759 12459004 1752755 0 200 0 4559016 6444947 4609794 4340434 0 0 0 0 662505 536597 161024 125908 2928505 2547644 0 0 0 0 1444518 1102740 13703057 14561673 2208449 3157781 187500 505259 0 0 1468591 1133192 3864540 4796232 X 9664680 9591604 173837 173837 9838517 9765441 13703057 14561673 -314313 241237 0 X false true X true false X X X 1 INDIANA UNIVERSITY 356001673 2 true 276504 0 1 276504 0 true false false false false false false false false false false false false false false true false 662505 536597 125908 125908 Right of Use Assets 1102740 1102740 Lease Liability 1133192 1133192 X 14138683 241237 0 241237 13897446 0 0 13897446 14211759 0 0 14211759 0 0 14211759 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Organization is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code and is not considered to be a private foundation. Current accounting standards require the Organization to disclose the amount of potential benefit or obligation to be realized as a result of an examination performed by a taxing authority. For the years ended June 30, 2024 and 2023, management has determined that the Organization does not have any tax positions that result in any uncertainties regarding the possible impact on the Organization's financial statements. The Organization does not expect the total amount of unrecognized tax benefits to significantly change in the next 12 months. The Organization recognizes interest and/or penalties related to income tax matters in income tax expense. The Organization did not have any amounts accrued for interest and penalties at June 30, 2024 and 2023. X X X false false false false false false false false false Patrick Loehrer MD Board Member 0 294382 0 0 0 0 0 0 0 0 0 294382 0 0 Brian Stemme CEO 286065 0 12875 0 0 0 10205 0 29194 0 338339 0 0 0 LeaEtta Hyer Research Development Officer 113908 0 16768 0 0 0 4187 0 25693 0 160556 0 0 0 Karen Dutcher General Counsel 140001 0 13281 0 0 0 4900 0 18690 0 176872 0 0 0 Form 990, Part VI, Line 1a Delegate broad authority to a committee The Executive Committee shall be composed entirely of directors. During intervals between meetings of the Board of Directors, the Executive Committee shall have and exercise all of the authority of the Board of Directors in the management of the Corporation, except where prohibited by law. In addition, the Executive Committee, to the extent specified by the Board of Directors, may exercise any other authority of the Board of Directors at such other times, except where prohibited by law. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body The Director of the Indiana University Melvin and Bren Simon Cancer Center has authority to appoint a majority of the Board of Directors. Form 990, Part VI, Line 11b Review of form 990 by governing body The form 990 is reviewed in detail by management. Then, a copy of the form 990 is provided to the Chairman for review before it is filed with the Internal Revenue Service. A copy of the 990 is also made available to the Board members prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy A written conflict of interest policy is signed by the board of directors and the CEO annually. The CEO reviews them and discloses any reported conflicts of interest to the board chair. The board chair ensures that any member who has a conflict of interest abstains from voting on issues related to the conflict. Form 990, Part VI, Line 15a Process to establish compensation of top management official The Officers of the Finance Committee review and approve the compensation of the CEO. The board uses performance review information to determine compensation, in conjunction with comparability data including forms 990 of other organizations. This process was last undergone in 2022. Form 990, Part VI, Line 19 Required documents available to the public Financial statements, governing documents, and conflict of interest policies are not required disclosures pursuant to Internal Revenue Code (IRC) Section 6104. These documents are not available to the public at this time. Form 990, Part VII, Section A, Line 1a Reportable Compensation from related organizations Compensation reported on Part VII and Schedule J for board members who are employees of Indiana University is the compensation annually reported and disclosed by the university as required under state statute. In addition, these individuals participate in retirement and benefit plan provided by the university. Indiana University 400 E 7th St Rm 501 Bloomington IN 47405 356001673 Education IN 501(c)(3) 2 NA false false false false false false false false false false false false false false false false true false false false